174 related articles for article (PubMed ID: 26496174)
1. Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation.
Nussinov R; Tsai CJ; Muratcioglu S; Jang H; Gursoy A; Keskin O
Expert Rev Proteomics; 2015; 12(6):669-82. PubMed ID: 26496174
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
[TBL] [Abstract][Full Text] [Related]
3. Depletion of K-Ras promotes proteasome degradation of survivin.
Tecleab A; Sebti SM
Cell Cycle; 2013 Feb; 12(3):522-32. PubMed ID: 23324341
[TBL] [Abstract][Full Text] [Related]
4. Oncogenesis and the clinical significance of K-ras in pancreatic adenocarcinoma.
Huang C; Wang WM; Gong JP; Yang K
Asian Pac J Cancer Prev; 2013; 14(5):2699-701. PubMed ID: 23803017
[TBL] [Abstract][Full Text] [Related]
5. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Mol Cancer Res; 2015 Sep; 13(9):1265-73. PubMed ID: 26085527
[TBL] [Abstract][Full Text] [Related]
6. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344
[TBL] [Abstract][Full Text] [Related]
7. Activated Ras induces cytoplasmic vacuolation and non-apoptotic death in glioblastoma cells via novel effector pathways.
Kaul A; Overmeyer JH; Maltese WA
Cell Signal; 2007 May; 19(5):1034-43. PubMed ID: 17210246
[TBL] [Abstract][Full Text] [Related]
8. Independent and core pathways in oncogenic KRAS signaling.
Nussinov R; Tsai CJ; Jang H
Expert Rev Proteomics; 2016 Aug; 13(8):711-6. PubMed ID: 27389825
[No Abstract] [Full Text] [Related]
9. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC
Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089
[TBL] [Abstract][Full Text] [Related]
10. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
11. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions.
Nakhaeizadeh H; Amin E; Nakhaei-Rad S; Dvorsky R; Ahmadian MR
PLoS One; 2016; 11(12):e0167145. PubMed ID: 27936046
[TBL] [Abstract][Full Text] [Related]
12. A novel potential effector of M-Ras and p21 Ras negatively regulates p21 Ras-mediated gene induction and cell growth.
Ehrhardt GR; Korherr C; Wieler JS; Knaus M; Schrader JW
Oncogene; 2001 Jan; 20(2):188-97. PubMed ID: 11313946
[TBL] [Abstract][Full Text] [Related]
13. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
14. Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase.
Lee J; Choi KJ; Lim MJ; Hong F; Choi TG; Tak E; Lee S; Kim YJ; Chang SG; Cho JM; Ha J; Kim SS
Cell Res; 2010 Aug; 20(8):919-34. PubMed ID: 20603646
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Ras signaling specificity by protein kinase C.
Rusanescu G; Gotoh T; Tian X; Feig LA
Mol Cell Biol; 2001 Apr; 21(8):2650-8. PubMed ID: 11283245
[TBL] [Abstract][Full Text] [Related]
16. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic protein disorder in oncogenic KRAS signaling.
Nussinov R; Jang H; Tsai CJ; Liao TJ; Li S; Fushman D; Zhang J
Cell Mol Life Sci; 2017 Sep; 74(17):3245-3261. PubMed ID: 28597297
[TBL] [Abstract][Full Text] [Related]
18. Prolonged vs transient roles for early cell cycle signaling components.
Rose DW; Xiao S; Pillay TS; Kolch W; Olefsky JM
Oncogene; 1998 Aug; 17(7):889-99. PubMed ID: 9780005
[TBL] [Abstract][Full Text] [Related]
19. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling.
Villalonga P; López-Alcalá C; Bosch M; Chiloeches A; Rocamora N; Gil J; Marais R; Marshall CJ; Bachs O; Agell N
Mol Cell Biol; 2001 Nov; 21(21):7345-54. PubMed ID: 11585916
[TBL] [Abstract][Full Text] [Related]
20. Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction.
Jang H; Banerjee A; Chavan T; Gaponenko V; Nussinov R
J Biol Chem; 2017 Jul; 292(30):12544-12559. PubMed ID: 28623230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]